ICOS-based chimeric antigen receptors program bipolar TH17/ TH1 cells

Blood

Volumn 124, Issue 7, 2014, Pages 1070-1080

  Guedan, Sonia ^a,b   Chen, Xi ^c   Madar, Aviv ^c   Carpenito, Carmine ^a   McGettigan, Shannon E ^a   Frigault, Matthew J ^a   Lee, Jihyun ^a   Posey Jr , Avery D ^a   Scholler, John ^a   Scholler, Nathalie ^a,d   Bonneau, Richard ^c,e   June, Carl H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c NEW YORK UNIVERSITY   (United States)

^d SRI INTERNATIONAL   (United States)

^e POLYTECHNIC UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CD161 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CELL PROTEIN; CHIMERIC ANTIGEN RECEPTOR; CHIMERIC PROTEIN; GAMMA INTERFERON; INDUCIBLE COSTIMULATOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 22; LYMPHOCYTE ANTIGEN RECEPTOR; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; CD3 ANTIGEN, ZETA CHAIN; HYBRID PROTEIN; IL2RG PROTEIN, MOUSE; INDUCIBLE T CELL COSTIMULATOR; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL EXPANSION; CELL ISOLATION; CELL POLARITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; FLOW CYTOMETRY; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH1 CELL; TH17 CELL; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL CULTURE; DRUG SCREENING; GENETICS; IMMUNOLOGY; K562 CELL LINE; KNOCKOUT MOUSE; METABOLISM; NONOBESE DIABETIC MOUSE; PROCEDURES; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD137; ANTIGENS, CD28; ANTIGENS, CD3; CELL LINE, TUMOR; CELLS, CULTURED; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INDUCIBLE T-CELL CO-STIMULATOR PROTEIN; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; INTERLEUKIN-17; INTERLEUKINS; K562 CELLS; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TH1 CELLS; TH17 CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905996839     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-10-535245     Document Type: Article

References (40)

1. Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells. J Immunol Methods. 2001;248(1-2):67-76. (Pubitemid 32167025)
2. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388-398.
3. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12(20 Pt 1):6106-6115. (Pubitemid 44703776)
4. Lamers CHJ, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006;24(13):e20-e22.
5. Mitsuyasu RT, Anton PA, Deeks SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood. 2000;96(3):785-793. (Pubitemid 30616838)
6. Brentjens RJ, Davila ML, Riviere I, et al. CD19-Targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.
7. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1518.
8. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12): 2709-2720.
9. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-733.
10. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264-1270.
11. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123-1132. (Pubitemid 41541790)
12. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6(11):1133-1141. (Pubitemid 41541791)
13. Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 2008;112(2):362-373.
14. Muranski P, Borman ZA, Kerkar SP, et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity. 2011;35(6):972-985.
15. Paulos CM, Carpenito C, Plesa G, et al. The inducible costimulator (ICOS) is critical for the development of human TH17 cells. Sci Transl Med. 2010;2(55):55ra78.
16. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27(1):485-517.
17. Muranski P, Restifo NP. Essentials of Th17 cell commitment and plasticity. Blood. 2013;121(13):2402-2414.
18. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity. 2006;24(6):677-688. (Pubitemid 43867371)
19. Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17(10):1290-1297.
20. Hinrichs CS, Borman ZA, Cassard L, et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci USA. 2009;106(41):17469-17474.
21. Wang X, Berger C, Wong CW, Forman SJ, Riddell SR, Jensen MC. Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood. 2011;117(6):1888-1898.
22. Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 2013;39(1):49-60.
23. Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA. 2009;106(9):3360-3365.
24. Parry RV, Rumbley CA, Vandenberghe LH, June CH, Riley JL. CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. J Immunol. 2003;171(1):166-174. (Pubitemid 36745285)
25. Bergan L, Gross JA, Nevin B, Urban N, Scholler N. Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin- dependent cell attachment. Cancer Lett. 2007;255(2):263-274. (Pubitemid 47268642)
26. Ciofani M, Madar A, Galan C, et al. A validated regulatory network for Th17 cell specification. Cell. 2012;151(2):289-303.
27. Riley JL, Mao M, Kobayashi S, et al. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc Natl Acad Sci USA. 2002;99(18):11790-11795. (Pubitemid 34994477)
28. Hinrichs CS, Kaiser A, Paulos CM, et al. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood. 2009;114(3):596-599.
29. Kalos M, Levine BL, Porter DL, et al. T Cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.
30. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol. 2005;175(10):7046-7052. (Pubitemid 41598952)
31. + T cells in metastases from melanoma patients. J Clin Invest. 2011;121(6):2350-2360.
32. Sharma MD, Huang L, Choi J-H, et al. An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity. 2013;38(5):998-1012.
33. Shen C-J, Yang Y-X, Han EQ, et al. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. J Hematol Oncol. 2013;6(1):33.
34. Cosmi L, De Palma R, Santarlasci V, et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med. 2008;205(8):1903-1916.
35. Kofler DM, Chmielewski M, Rappl G, et al. CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory T cells which can be overcome by preventing Lck activation. Mol Ther. 2011;19(4):760-767.
36. Chen H, Liakou CI, Kamat A, et al. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci USA. 2009;106(8):2729-2734.
37. Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med. 2014;211(4):715-725.
38. Ng Tang D, Shen Y, Sun J, et al. Increased frequency of ICOS1 CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res. 2013;1(4):229-234.
39. Gulen MF, Bulek K, Xiao H, et al. Inactivation of the enzyme GSK3a by the kinase IKKi promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17 cell maintenance. Immunity. 2012;37(5):800-812.
40. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006;116(7):1935-1945. (Pubitemid 44033317)